CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinue production of Fluorognost HIV-1 IFA test kits routinely used for confirmation of HIV-1 antibody-reactive donations. Based on our current testing volume, CTS has sufficient HIV-1 IFA reagent inventory to continue performing this confirmatory test through the end of August 2019.
Check out the Communication page for the complete details on the updated IFA HIV-1 assay or by clicking the link: Communications
CTS Tampa has implemented the Ortho Vitros Anti-SARS-CoV-2 Total test which qualitatively detects an...
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
This is the first update to the original CTS communication distributed on July 6th. As previously co...
CTS Spotlight at 2018 AABB Annual Meeting Sunday, October 14, 2018 at 1:30 PM: Scientific Oral ...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...